Alltracel teams up with Elmarco

DUBLIN-BASED medical technology company Alltracel has entered into a joint-venture agreement with the Czech-based nanotechnology R&D company Elmarco, with which it already has a research agreement.

Alltracel's main expertise is in the wound care, oral care and cardiovascular health markets. Its main product is its 'm-doc' technology, which stops bleeding.

Earlier this year, the company developed a nano-fibre based delivery system for m-doc — the new joint venture is aimed at bringing this to market.